Northern Trust’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.2M Buy
781,418
+19,945
+3% +$596K ﹤0.01% 1581
2025
Q4
$29.1M Sell
761,473
-70,606
-8% -$2.3M ﹤0.01% 1431
2025
Q3
$19.9M Buy
832,079
+31,451
+4% +$591K ﹤0.01% 1688
2025
Q2
$11.8M Sell
800,628
-8,059
-1% -$134K ﹤0.01% 1965
2025
Q1
$14.5M Buy
808,687
+54,292
+7% +$1.1M ﹤0.01% 1823
2024
Q4
$13.1M Buy
754,395
+76,358
+11% +$1.35M ﹤0.01% 1966
2024
Q3
$9.49M Sell
678,037
-26,525
-4% -$276K ﹤0.01% 2096
2024
Q2
$5.79M Sell
704,562
-19,467
-3% -$131K ﹤0.01% 2316
2024
Q1
$5.58M Sell
724,029
-6,117
-0.8% -$51.6K ﹤0.01% 2381
2023
Q4
$6.56M Buy
730,146
+40,126
+6% +$292K ﹤0.01% 2335
2023
Q3
$6.17M Buy
690,020
+5,887
+0.9% +$83.1K ﹤0.01% 2314
2023
Q2
$10.5M Sell
684,133
-6,768
-1% -$123K ﹤0.01% 2028
2023
Q1
$15.5M Buy
690,901
+54,176
+9% +$1.15M ﹤0.01% 1721
2022
Q4
$13.4M Buy
636,725
+4,580
+0.7% +$97.1K ﹤0.01% 1810
2022
Q3
$15.6M Sell
632,145
-4,369
-0.7% -$113K ﹤0.01% 1673
2022
Q2
$15.4M Buy
636,514
+10,254
+2% +$258K ﹤0.01% 1717
2022
Q1
$16.1M Buy
626,260
+70,464
+13% +$1.87M ﹤0.01% 1821
2021
Q4
$17.3M Sell
555,796
-4,819
-0.9% -$136K ﹤0.01% 1880
2021
Q3
$13.6M Sell
560,615
-58,130
-9% -$1.07M ﹤0.01% 2063
2021
Q2
$9.03M Sell
618,745
-22,176
-3% -$437K ﹤0.01% 2445
2021
Q1
$16M Buy
640,921
+26,024
+4% +$719K ﹤0.01% 1984
2020
Q4
$16.8M Sell
614,897
-19,072
-3% -$445K ﹤0.01% 1923
2020
Q3
$11.7M Buy
633,969
+39,635
+7% +$770K ﹤0.01% 2014
2020
Q2
$12.1M Buy
594,334
+30,420
+5% +$484K ﹤0.01% 1987
2020
Q1
$8.23M Buy
563,914
+5,663
+1% +$85.2K ﹤0.01% 1998
2019
Q4
$7.93M Buy
558,251
+4,203
+0.8% +$53.7K ﹤0.01% 2327
2019
Q3
$6.42M Buy
554,048
+20,971
+4% +$347K ﹤0.01% 2403
2019
Q2
$10.7M Buy
533,077
+2,880
+0.5% +$56.9K ﹤0.01% 2109
2019
Q1
$12M Sell
530,197
-230,299
-30% -$5.09M ﹤0.01% 2031
2018
Q4
$17.2M Buy
760,496
+4,277
+0.6% +$106K ﹤0.01% 1697
2018
Q3
$21.7M Sell
756,219
-2,374
-0.3% -$67.9K 0.01% 1732
2018
Q2
$20.7M Buy
758,593
+45,069
+6% +$1.2M 0.01% 1758
2018
Q1
$16M Buy
713,524
+12,513
+2% +$298K ﹤0.01% 1859
2017
Q4
$14.8M Sell
701,011
-12,336
-2% -$282K ﹤0.01% 1934
2017
Q3
$17.8M Buy
713,347
+5,099
+0.7% +$112K ﹤0.01% 1792
2017
Q2
$13.7M Buy
708,248
+26,119
+4% +$474K ﹤0.01% 1957
2017
Q1
$12.6M Buy
682,129
+24,461
+4% +$478K ﹤0.01% 1952
2016
Q4
$12.4M Buy
657,668
+269,390
+69% +$5.51M ﹤0.01% 1956
2016
Q3
$8.69M Buy
388,278
+8,839
+2% +$168K ﹤0.01% 2171
2016
Q2
$6.76M Sell
379,439
-14,452
-4% -$234K ﹤0.01% 2275
2016
Q1
$5.38M Sell
393,891
-2,023
-0.5% -$30.7K ﹤0.01% 2367
2015
Q4
$7.64M Buy
395,914
+22,473
+6% +$449K ﹤0.01% 2195
2015
Q3
$7.57M Buy
373,441
+68,499
+22% +$2.03M ﹤0.01% 2178
2015
Q2
$10.1M Buy
304,942
+75,885
+33% +$2.08M ﹤0.01% 2062
2015
Q1
$5.49M Buy
229,057
+16,472
+8% +$251K ﹤0.01% 2450
2014
Q4
$2.6M Sell
212,585
-8,544
-4% -$88.4K ﹤0.01% 2933
2014
Q3
$2M Buy
221,129
+35,770
+19% +$421K ﹤0.01% 3107
2014
Q2
$2.18M Buy
185,359
+141,444
+322% +$1.92M ﹤0.01% 3043
2014
Q1
$931K Buy
+43,915
New +$675K ﹤0.01% 3416

Other funds holding TVTX

Northern Trust's TVTX Position: Q1 2026 in Review

Northern Trust increased its Travere Therapeutics (TVTX) stake by 2.6% in Q1 2026, buying an estimated $596K and bringing the position to 781,418 shares worth $23.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1581.

Northern Trust first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $29.1M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Northern Trust held 781,418 shares of Travere Therapeutics worth $23.2M as of Q1 2026.
  • Northern Trust bought 19,945 Travere Therapeutics shares in Q1 2026, an estimated $596K.
  • Travere Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1581 holding.
  • Northern Trust first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Northern Trust's Travere Therapeutics position peaked at $29.1M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.